2 completed. 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 2 | Completed 2 |
Follow Cell Transformation, Neoplastic: new trials by email Literature Review of Cell Transformation, Neoplastic trials Research Report on Cell Transformation, Neoplastic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial nilotinib - Chronic Myelogenous Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 19 | 2008-12-01 | 2016-11-16 |
| Bone Marrow Transplantation in Treating Patients With Hematologic Cancer anti-thymocyte globulin, filgrastim, cyclophosphamide - Anemia, Graft Versus Host Disease | Phase 4 | Completed | University of Maryland, Baltimore | 45 | 1998-09-01 | 2019-10-17 |
Blast Crisis (2) · Anemia (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Leukemia (1) · Leukemia, Basophilic, Acute (1) · Leukemia, Eosinophilic, Acute (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Megakaryoblastic, Acute (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myeloid, Chronic-Phase (1)
Bone Marrow Diseases (2) · Carcinogenesis (2) · Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia, Myeloid (2) · Myeloproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Blood Protein Disorders (1)
Antilymphocyte Serum (1) · Cyclophosphamide (1) · Filgrastim (1) · Radiotherapy (1) · Thiotepa (1) · nilotinib (1)
Novartis Pharmaceuticals (1) · University of Maryland, Baltimore (1)
Poland (1) · United States (1)